Solara Active Pharma Sciences' Q4 FY 2025-26 Quarterly Results

Result Summary

• Solara Active Pharma Sciences Ltd reported a 12.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 40.5%.
• Its expenses for the quarter were up by 6.6% QoQ and 36.4% YoY.
• The net profit decreased 155.1% QoQ and decreased 557.1% YoY.
• The earnings per share (EPS) of Solara Active Pharma Sciences Ltd stood at 2.2 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Solara Active Pharma Sciences Ltd is a company primarily engaged in the pharmaceutical industry. While specific details about its main products or services are not provided in the given data, it is likely involved in the production and sale of active pharmaceutical ingredients (APIs) and other related pharmaceutical products. Recent major developments or strategic initiatives are not included within the scope of this data. Solara Active Pharma Sciences operates within a dynamic sector that is subject to regulatory changes, innovation, and market demand shifts.

Revenue

For the fourth quarter of fiscal year 2026 (Q4FY26), Solara Active Pharma Sciences Ltd reported a total income of ₹391.98 crores. This represents a quarter-over-quarter (QoQ) increase of 12.3% from the previous quarter (Q3FY26), where total income was ₹349.00 crores. Year-over-year (YoY), the company experienced a significant increase of 40.5% in total income compared to ₹278.96 crores in Q4FY25. These figures suggest notable revenue growth over both the quarterly and annual periods captured in the financial data.

Profitability

The profitability metrics for Solara Active Pharma Sciences Ltd in Q4FY26 indicate a profit before tax of ₹9.60 crores. This is a turnaround from a loss before tax of ₹17.43 crores in Q3FY26 and a loss of ₹2.10 crores in Q4FY25, marking a QoQ improvement of -155.1% and a YoY improvement of -557.1%. The profit after tax mirrors these figures, as there was no tax expense reported. Earnings per share (EPS) for Q4FY26 was ₹2.20, compared to -₹3.98 in Q3FY26 and -₹0.93 in Q4FY25, reflecting a QoQ change of -155.3% and a YoY change of -336.6%.

Operating Metrics

The financial performance for Solara Active Pharma Sciences Ltd in Q4FY26 also involves examining total expenses, which amounted to ₹383.24 crores. This is a QoQ increase of 6.6% from ₹359.68 crores in Q3FY26 and a YoY increase of 36.4% from ₹281.06 crores in Q4FY25. The substantial changes in both income and expenses, along with the transition from losses to profitability, are significant aspects of the company's operating metrics for this quarter. The data provided does not include specific financial ratios or detailed operating metrics such as the P/E ratio, debt-to-equity ratio, or current ratio.